Mass Cytometry (CyTOF): A New Tool in Non-Hodgkin's Lymphoma Research

Researchers

Project description

The research team is studying the application of mass cytometry (CyTOF) technology to better understand and treat non-Hodgkin's lymphoma. Earlier projects using CyTOF in this way had been funded through the Minnesota Partnership for Biotechnology and Medical Genomics — a collaboration between Mayo Clinic and the University of Minnesota — and showed promising results.

Dr. Villasboas Bisneto, under Dr. Ansell's mentorship, spearheaded a pilot project to study immune cells in biopsies from patients with lymphoma using the CyTOF system housed at the University of Minnesota in Minneapolis.

Research by Drs. Villasboas Bisneto, Ansell and Pavelko identified key differences in immune cell populations by using CyTOF to compare normal tissue with biopsy samples from patients diagnosed with lymphoma. The findings from their study are being summarized for publication.

Impact on patient care

In non-Hodgkin's lymphoma, cells that normally function as immune cells become cancer cells. Treating the lymphoma requires active participation of the patient's immune system. Trying to study the lymphoma cells themselves and their interactions with other immune cells is a complex task.

The field of cancer research will profit from better technologies that enable the study of cancer cells and the immune system at the same time. Additionally, these technologies must be able to work on small amounts of tissue obtained from patients during biopsies, many times done with minuscule needles.

This cutting-edge work served to illustrate the power of CyTOF to other researchers at Mayo Clinic, leading to the creation of the Immune Monitoring Core. The Immune Monitoring Core houses a latest-generation CyTOF system that enables Mayo Clinic researchers to continue to advance the understanding of non-Hodgkin's lymphoma and other diseases and conditions.

Funding

These discoveries and advances were made through the generous support of the Landow Family Fund.